OncoMatch/Clinical Trials/NCT06060613
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Official title: A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Advanced Solid Tumors
Is NCT06060613 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies OBX-115 for tumor skin.
Treatment: OBX-115 — This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: GNA11 mutation
Excluded: GNAQ mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy or anti-PD-L1 therapy — systemic therapy for melanoma
Participants with unresectable or metastatic melanoma must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody.
Cannot have received: BRAF inhibitor and/or MEK inhibitor
Exception: Participants with targetable BRAF mutations are not required to have received prior BRAF inhibitors. Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy.
Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy.
Lab requirements
Blood counts
protocol specified hematologic parameters for absolute neutrophil count (anc) and platelet count
Kidney function
adequate kidney function as specified in the protocol
Liver function
adequate liver function as specified in the protocol
Cardiac function
adequate cardiac function as specified in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute (Melanoma) · Los Angeles, California
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC) · Los Angeles, California
- Stanford Cancer Institute (Melanoma/NSCLC) · Stanford, California
- Orlando Health Cancer Institute (Melanoma/NSCLC) · Orlando, Florida
- James Graham Brown Cancer Center (Melanoma/NSCLC) · Louisville, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06060613 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BRAF inhibitor and/or MEK inhibitor disqualifies patients from enrollment.
Are patients with GNA11 alterations eligible?
No. GNA11 mutation is an exclusion criterion.
Are patients with GNAQ alterations eligible?
No. GNAQ mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages